Close Menu

Goldman Sachs

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

The downgrades to Illumina and Waters reflect larger worries the investment bank has about the end markets of life science tools firms.

In a research note, the investment house cited concerns about Cepheid's high price-to-sale ratio but said that the firm's installed base is expected to grow 27 percent year over year in 2011.

A report on Goldman Sachs' evaluations of Illumina and Life Technologies' desktop next-generation sequencing platforms once again was the most-read story on GWDN during the past week.

The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.

Though Illumina has been predicting a second round of association studies run on chips containing rare variant content, CEO Jay Flatley said that the market is "at the very beginning" of this new phase, which Illumina refers to as "rich GWAS."

Pages

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.